{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:15:19Z","timestamp":1788974119250,"version":"build-2803163510"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synthetic Opioids and the rising polysubstance use have caused a substantial change in the epidemiology of opioid use disorder (OUD) in the United States. Current overdose patterns may no longer be adequately explained by traditional opioid-driven theories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured review was conducted using PRISMA-informed methods. Literature published between 2010 and 2026 was identified through PubMed, Scopus, and Google Scholar using terms related to OUD, fentanyl, polysubstance use, and treatment strategies. Eligible sources included peer-reviewed studies and government reports addressing epidemiology, risk factors, and interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A polysubstance-driven milieu marked by fentanyl monopoly, stimulant co-use, and new adulterants like xylazine and nitazenes has resulted from the opioid crisis\u2019s evolution through several phases. A regional evaluation of South Florida shows how current drug market trends and past prescribing practices converge to increase the risk of overdose. Structural inequities, like unstable finances and limited access to therapy, continue to affect OUD outcomes. Systemic barriers also make evidence-based treatments less effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Opioid use disorder needs to be recognized within a wider context of polysubstance risk rather than seen as a solely opioid issue. Successful strategies demand comprehensive policy responses, enhanced harm reduction measures, and flexible surveillance systems that can adapt to rapid shifts in drug availability and usage trends.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1861122","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:44:37Z","timestamp":1788972277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolving epidemiology of opioid use disorder: polysubstance use, drug supply transformation, and policy implications"],"prefix":"10.3389","volume":"14","author":[{"given":"Naga Koushik","family":"Mandapati","sequence":"first","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Cardenas","family":"Tovar","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Bindlish","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesenia Lopez","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele J.","family":"Alves","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna K.","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1080\/13696998.2025.2602385","article-title":"Societal burden of the US opioid epidemic over the next 15 years and the potential impact of effective non-opioid treatments for pain","volume":"28","author":"Ballreich","year":"2025","journal-title":"J Med Econ"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1176\/appi.ajp.2015.15020262","article-title":"Prescription opioid misuse, abuse, and treatment in the United States: an update","volume":"173","author":"Brady","year":"2016","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"209484","DOI":"10.1016\/j.josat.2024.209484","article-title":"A scoping review of social determinants of health's impact on substance use disorders over the life course","volume":"166","author":"Lin","year":"2024","journal-title":"J Subst Use Addict Treat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2105\/AJPH.2015.302953","article-title":"Opioid overdose deaths and Florida's crackdown on pill Mills","volume":"106","author":"Kennedy-Hendricks","year":"2016","journal-title":"Am J Public Health"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.36518\/2689-0216.1304","article-title":"A call to action: preventing opioid and substance abuse in South Florida youth","volume":"2","author":"Jacko","year":"2021","journal-title":"HCA Healthc J Med"},{"key":"ref7","volume-title":"New NIH Study Reveals Shared genetic Markers Underlying Substance use Disorders","year":"2023"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"117137","DOI":"10.1016\/j.jns.2020.117137","article-title":"Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): do homo sapiens acquire or have a reward deficiency syndrome?","volume":"418","author":"Gold","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"Int J Drug Policy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/002204261004000307","article-title":"Prescription drug abuse and diversion: role of the pain clinic","volume":"40","author":"Rigg","year":"2010","journal-title":"J Drug Issues"},{"key":"ref12","volume-title":"SUDORS Dashboard: Fatal Drug Overdose Data","year":"2026"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"107625","DOI":"10.1016\/j.ypmed.2023.107625","article-title":"The fourth wave of the overdose crisis: examining the prominent role of psychomotor stimulants with and without fentanyl","volume":"176","author":"Rawson","year":"2023","journal-title":"Prev Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41380-020-00949-3","article-title":"Polysubstance use in the U.S. opioid crisis","volume":"26","author":"Compton","year":"2021","journal-title":"Mol Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/jama.2025.13881","article-title":"More than half of US overdose deaths now involve stimulants","volume":"334","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.15585\/mmwr.rr7103a1","article-title":"Nitazenes: an old drug class causing new problems","volume":"122","author":"Schwarz","year":"2025","journal-title":"Mo Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/molecules30193890","article-title":"Nitazenes: the emergence of a potent synthetic opioid threat","volume":"30","author":"Pereira","year":"2025","journal-title":"Molecules"},{"key":"ref18","volume-title":"The Dangers of Mixing Opioids with Alcohol and other Drugs","author":"Mosel","year":"2026"},{"key":"ref19","volume-title":"New Safety Measures Announced for opioid Analgesics, Prescription opioid Cough Products, and Benzodiazepines","year":"2016"},{"key":"ref20","volume-title":"Benzodiazepines and Opioids","year":"2022"},{"key":"ref21","volume-title":"Alcohol-Medication Interactions: Potentially Dangerous Mixes","year":"2025"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e202361","DOI":"10.1001\/jamanetworkopen.2020.2361","article-title":"Alcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999-2017","volume":"3","author":"Tori","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref23","volume-title":"FDA Alerts Health care Professionals of Risks to Patients Exposed to Xylazine in illicit Drugs","year":"2022"},{"key":"ref24","volume-title":"Statement from DEA Administrator Anne Milgram on the Increase in DEA Fentanyl Seizures Containing Xylazine","author":"Milgram","year":"2024"},{"key":"ref25","volume-title":"DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine","year":"2023"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e36864","DOI":"10.7759\/cureus.36864","article-title":"Xylazine in the opioid epidemic: a systematic review of Case reports and clinical implications","volume":"15","author":"Ayub","year":"2023","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fnins.2020.00569","article-title":"One is not enough: understanding and modeling polysubstance use","volume":"14","author":"Crummy","year":"2020","journal-title":"Front Neurosci"},{"key":"ref28","volume-title":"Overdose Deaths are down Nationally but up in many Western states","author":"Henderson","year":"2024"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"104063","DOI":"10.1016\/j.drugpo.2023.104063","article-title":"Understanding intentionality of fentanyl use and drug overdose risk: findings from a mixed methods study of people who inject drugs in new York City","volume":"118","author":"McKnight","year":"2023","journal-title":"Int J Drug Policy"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"112630","DOI":"10.1016\/j.drugalcdep.2025.112630","article-title":"National trends in co-use of opioids and methamphetamine among people who inject drugs, 2012-2018","volume":"271","author":"Reid","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/ajad.13115","article-title":"Increasing heroin-methamphetamine (goofball) use and related morbidity among Seattle area people who inject drugs","volume":"30","author":"Glick","year":"2021","journal-title":"Am J Addict"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"824940","DOI":"10.3389\/fpsyt.2022.824940","article-title":"Patterns of and rationale for the co-use of methamphetamine and opioids: findings from qualitative interviews in New Mexico and Nevada","volume":"13","author":"Rhed","year":"2022","journal-title":"Front Psych"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/10826084.2016.1271432","article-title":"Heroin and methamphetamine injection: an emerging drug use pattern","volume":"52","author":"Al-Tayyib","year":"2017","journal-title":"Subst Use Misuse"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.15288\/jsad.2016.77.774","article-title":"Prevalence and correlates of heroin-methamphetamine co-injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico","volume":"77","author":"Meacham","year":"2016","journal-title":"J Stud Alcohol Drugs"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/10826084.2020.1765805","article-title":"Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern U.S. city","volume":"55","author":"Daniulaityte","year":"2020","journal-title":"Subst Use Misuse"},{"key":"ref36","volume-title":"Drug Abuse and Addiction Statistics in Florida","author":"Siegel","year":"2025"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drugalcdep.2015.02.010","article-title":"Abrupt decline in oxycodone-caused mortality after implementation of Florida's prescription drug monitoring program","volume":"150","author":"Delcher","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"ref38","year":"2023"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/pharmacy12040102","article-title":"Dynamic changes in the distribution of hydrocodone and oxycodone in Florida from 2006 to 2021","volume":"12","author":"Stains","year":"2006","journal-title":"Pharmacy"},{"key":"ref40","volume-title":"Deadly Contaminated Cocaine Widespread in Florida","year":"2018"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"112784","DOI":"10.1016\/j.drugalcdep.2025.112784","article-title":"Another carfentanil fatal outbreak in Florida?","volume":"274","author":"Delcher","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"ref42","volume-title":"2022 Florida Medical Examiners Annual Drug Report","year":"2022"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1377\/hlthaff.2015.1673","article-title":"Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians","volume":"35","author":"Bao","year":"2016","journal-title":"Health Aff"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/pm\/pnab017","article-title":"Changes in quantity of opioids dispensed following Florida's restriction law for acute pain prescriptions","volume":"22","author":"Hincapie-Castillo","year":"2021","journal-title":"Pain Med"},{"key":"ref45","volume-title":"Deaths of Despair and the Future of Capitalism","author":"Case","year":"2020"},{"key":"ref46","year":"2024"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jadohealth.2022.05.001","article-title":"An urgent need to focus on youth with opioid use disorder","volume":"71","author":"Wilson","year":"2022","journal-title":"J Adolesc Health"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40266-021-00893-z","article-title":"Problematic opioid use among older adults: epidemiology, adverse outcomes and treatment considerations","volume":"38","author":"Dufort","year":"2021","journal-title":"Drugs Aging"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.prcp.20190051","article-title":"Opioid use disorder in women and the implications for treatment","volume":"3","author":"Barbosa-Leiker","year":"2021","journal-title":"Psychiatr Res Clin Pract"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/YCO.0000000000000337","article-title":"Sex differences in prescription opioid use","volume":"30","author":"Serdarevic","year":"2017","journal-title":"Curr Opin Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1526-4637.2012.01467.x","article-title":"Medical and psychological risks and consequences of long-term opioid therapy in women","volume":"13","author":"Darnall","year":"2012","journal-title":"Pain Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s40615-022-01384-6","article-title":"The opioid epidemic: a crisis disproportionately impacting black Americans and urban communities","volume":"10","author":"Gondr\u00e9-Lewis","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"108927","DOI":"10.1016\/j.drugalcdep.2021.108927","article-title":"Racial inequity in medication treatment for opioid use disorder: exploring potential facilitators and barriers to use","volume":"227","author":"Hollander","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"ref55","doi-asserted-by":"crossref","DOI":"10.17226\/24781","volume-title":"Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use","author":"Bonnie","year":"2017"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e0227966","DOI":"10.1371\/journal.pone.0227966","article-title":"Socioeconomic risk factors for fatal opioid overdoses in the United States: findings from the mortality disparities in American communities study (MDAC)","volume":"15","author":"Altekruse","year":"2020","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.drugalcdep.2017.06.040","article-title":"The genetic epidemiology of substance use disorder: a review","volume":"180","author":"Prom-Wormley","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3892\/etm.2021.9976","article-title":"Understanding the genetics and neurobiological pathways behind addiction (review)","volume":"21","author":"Popescu","year":"2021","journal-title":"Exp Ther Med"},{"key":"ref59","author":"Mavrikaki","year":"2019"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"10434","DOI":"10.1073\/pnas.1811940115","article-title":"Human endogenous retrovirus-K HML-2 integration within RASGRF2 is associated with intravenous drug abuse and modulates transcription in a cell-line model","volume":"115","author":"Karamitros","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref61","year":"2025"},{"key":"ref62","volume-title":"Naltrexone","author":"Singh","year":"2023"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e255023","DOI":"10.1001\/jamahealthforum.2025.5023","article-title":"Trends in methadone use for pain and opioid use disorder among Medicaid enrollees","volume":"6","author":"Hsu","year":"2025","journal-title":"JAMA Health Forum"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e41621","DOI":"10.7759\/cureus.41621","article-title":"The opioid epidemic: a review of the contributing factors, negative consequences, and best practices","volume":"15","author":"Judd","year":"2023","journal-title":"Cureus"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamainternmed.2024.3422","article-title":"Addiction consultation services for opioid use disorder treatment initiation and engagement: a randomized clinical trial","volume":"184","author":"McNeely","year":"2024","journal-title":"JAMA Intern Med"},{"key":"ref66","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health","year":"2023"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e41464","DOI":"10.7759\/cureus.41464","article-title":"Demographics and clinical characteristics of patients with opioid use disorder and offered medication-assisted treatment in the emergency department","volume":"15","author":"Fu","year":"2023","journal-title":"Cureus"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates \u2013 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref69","author":"Swift","year":"2025"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trsl.2021.03.001","article-title":"Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities","volume":"234","author":"Bennett","year":"2021","journal-title":"Transl Res"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"04","DOI":"10.35946\/arcr.v41.1.04","article-title":"The emergence, role, and impact of recovery support services","volume":"41","author":"Jason","year":"2021","journal-title":"Alcohol Res"},{"key":"ref72","year":""},{"key":"ref73","year":"2026"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1038\/s41591-025-03603-z","article-title":"Clinical implementation of AI-based screening for risk for opioid use disorder in hospitalized adults","volume":"31","author":"Afshar","year":"2025","journal-title":"Nat Med"},{"key":"ref75","author":"Rozenblum","year":"2024"},{"key":"ref76","year":"2025"},{"key":"ref77","year":"2025"},{"key":"ref78","year":"2024"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/ccp0000552","article-title":"Long-term efficacy of contingency management treatment based on objective indicators of abstinence from illicit substance use up to 1 year following treatment: a meta-analysis","volume":"89","author":"Ginley","year":"2021","journal-title":"J Consult Clin Psychol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jsat.2013.12.007","article-title":"Disseminating contingency management: impacts of staff training and implementation at an opiate treatment program","volume":"46","author":"Hartzler","year":"2014","journal-title":"J Subst Abus Treat"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/ADM.0000000000000323","article-title":"Appropriate use of drug testing in clinical addiction medicine","volume":"11","author":"Jarvis","year":"2017","journal-title":"J Addict Med"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"108693","DOI":"10.1016\/j.jsat.2021.108693","article-title":"Contingency management for alcohol use disorder reduces cannabis use among American Indian and Alaska native adults","volume":"137","author":"Hirchak","year":"2022","journal-title":"J Subst Abus Treat"},{"key":"ref83","volume-title":"Advisory","year":"2023"},{"key":"ref84","year":"2025"},{"key":"ref85","year":"2024"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for pain \u2014 United States","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1861122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:44:41Z","timestamp":1788972281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1861122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":86,"alternative-id":["10.3389\/fpubh.2026.1861122"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1861122","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1861122"}}